ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
— Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA®
ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, today announced the expansion of its ongoing Phase I clinical trial of IOS-1002 in combination with MSD (Merck & Co., Inc., Rahway, NJ, USA)’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of advanced solid tumors.
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
— Favorable safety profile of resorbable breast scaffolds in one-year follow-up
— No major scaffold-related complications or scaffold removals
— BellaSeno will initiate multicenter pivotal clinical trial with more than 100 patients
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that 10 breast scaffold patients and 5 pectus patients have successfully passed one-year follow-up in BellaSeno´s Australian clinical trials.
Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer
– Experienced biopharma professional focused on drug product development
Thermosome, a drug development company focused on targeted tumor therapies, today announced the appointment of Dr. Sabine Hauck as Chief Technology Officer (CTO).
Dr. Sabine Hauck is a highly experienced biopharmaceutical professional. She has been working in the field of drug product development in biopharma and specialty pharma for more than 20 years. Notably, she brings more than a decade of experience with liposomal products. Her expertise covers process development, chemistry, manufacturing and controls as well as bioanalytics, quality management and regulatory affairs. Read more…
